Bioequivalence of domestic and imported bisoproloi tablets

Xiao-guang LI,Rong-sheng ZHAO,Suo-di ZHAI,Feng-rong CHEN,Zi-jing MA
DOI: https://doi.org/10.3321/j.issn:1003-3734.2005.05.029
2005-01-01
Abstract:Objective: To assess whether bisoprolol tablets locally manufactured (test) are bioequivalent to bisoprolol tablets imported (reference). Methods: 20 healthy male volunteers were randomly administered either a single crossover dose 10mg of both bisoprolol tablets. The blood samples from the volunteers were collected before and in 0.5~48h after dosing to measure plasma drug concentrations by HPLC-fluorescence spectrometer. The HPLC condition was as follows:a KYA HiQsil column (150mm×4.6mm,5μm), an eluant composed of acetonitrile-water-1mol·L~(-1) ammonium dihydrogen phosphate (25:70:5) with the flow rate of 1.0mL·min~(-1), and the detection at Ex=226nm and Em=300nm, respectively. Results: A linear curve of bisoprolol was in the range of 2.5~80.0ng·mL~(-1) and a detection limit was at 2.5ng·mL~(-1). The average recovery was within 100.20%~104.26% with within-day and among-days RSD of less than 5%. The pharmacokinetics parameters of test and reference tablets were shown as C_(max)(52.94±12.21) vs. (57.63±9.82) ng·mL~(-1), T_(max)(1.65± 0.59)vs.(1.55±0.54)h,t(1/2)(12.15±1.47) vs. (11.94±2.16) h,AUC_(0~t)(680.55±138.08) vs. (715.18±124.22)ng·mL~(-1)·h and AUC_(0~∞) (742.90±151.48)vs. (781.00± 141.28)ng·mL~(-1)·h. The relative bioavailability of test tablets was F_(0~t)(95.98±16.12)% and F_(0~∞) (95.99±15.74)%. Conclusion:The test tablets are bioequivalent to the reference tablets.
What problem does this paper attempt to address?